Home Tags ASCENT-04/KEYNOTE-D19

Tag: ASCENT-04/KEYNOTE-D19

Sacituzumab Govitecan Plus Pembrolizumab Sustains Clinical Benefit Beyond First Progression in...

Peter Hofland
Triple-negative breast cancer (TNBC) remains one of the most challenging and most malignant subtypes of breast cancer to treat. TNBC represents a heterogeneous group...

Phase 3 Study Supports Sacituzumab Govitecan + Pembrolizumab as a Potential...

Danielle Garcia
Phase 3 Study Supports Sacituzumab Govitecan + Pembrolizumab as a Potential New Standard of Care in First-line PD-L1+ mTNBC